Background: The aim of this study was to observe the effects of neoadjuvant therapy with irinotecan and 5-fluorouracil (5-FU)/folinic acid (FA) on the resection rate and survival of colorectal cancer patients with initially unresectable hepatic metastases. Patients and methods: Forty patients received neoadjuvant chemotherapy comprising irinotecan 180 mg/m(2) administered intravenously (i.v.) on day 1, FA 200 mg/m(2) i.v. on days I and 2, 5-FU 400 mg/m(2) i.v. bolus on days I and 2, and 5-FU 1200 mg/m(2) as a continuous 48-h i.v. infusion on day 1. The treatment was repeated every 2 weeks and response was assessed every 12 weeks (six cycles). Results: The objective response rate to chemotherapy was 47.5% (it = 19), with two complete responses and disease stabilization in H (27.5.%) patients. Responses were unconfirmed for I I patients undergoing surgery within 2 weeks. Treatment was well tolerated and adverse events were typical of the chemotherapy agents used. Twenty-seven (67.5%) patients reported hematological toxicity (35.0% grade 3/4) and 14 (35.0%) reported gastrointestinal toxicity (12.5% grade 3/4). Thirteen patients (32.5%) underwent potentially curative liver resection following chemotherapy. Chemotherapy was particularly effective in patients with large metastases on entry to the study. The median time to progression is 14.3 months and, at a median follow-up of 19 months, all patients are alive. Conclusions: Neoadjuvant therapy with irinotecan combined with 5-FU/FA enabled a significant proportion of patients with initially unresectable liver metastases to undergo surgical resection. The effects of treatment on survival have yet to be determined.

Pozzo, C., Basso, M., Cassano, A., Quirino, M., Schinzari, G., Trigila, N., Vellone, M., Giuliante, F., Nuzzo, G., Barone, C. A., Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients, <<ANNALS OF ONCOLOGY>>, 2004; 15 (6): 933-939. [doi:10.1093/annonc/mdh217] [http://hdl.handle.net/10807/14758]

Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients

Pozzo, Carmelo;Basso, Michele;Cassano, Alessandra;Quirino, Michela;Schinzari, Giovanni;Trigila, Nunziatina;Vellone, Maria;Giuliante, Felice;Nuzzo, Gennaro;Barone, Carlo Antonio
2004

Abstract

Background: The aim of this study was to observe the effects of neoadjuvant therapy with irinotecan and 5-fluorouracil (5-FU)/folinic acid (FA) on the resection rate and survival of colorectal cancer patients with initially unresectable hepatic metastases. Patients and methods: Forty patients received neoadjuvant chemotherapy comprising irinotecan 180 mg/m(2) administered intravenously (i.v.) on day 1, FA 200 mg/m(2) i.v. on days I and 2, 5-FU 400 mg/m(2) i.v. bolus on days I and 2, and 5-FU 1200 mg/m(2) as a continuous 48-h i.v. infusion on day 1. The treatment was repeated every 2 weeks and response was assessed every 12 weeks (six cycles). Results: The objective response rate to chemotherapy was 47.5% (it = 19), with two complete responses and disease stabilization in H (27.5.%) patients. Responses were unconfirmed for I I patients undergoing surgery within 2 weeks. Treatment was well tolerated and adverse events were typical of the chemotherapy agents used. Twenty-seven (67.5%) patients reported hematological toxicity (35.0% grade 3/4) and 14 (35.0%) reported gastrointestinal toxicity (12.5% grade 3/4). Thirteen patients (32.5%) underwent potentially curative liver resection following chemotherapy. Chemotherapy was particularly effective in patients with large metastases on entry to the study. The median time to progression is 14.3 months and, at a median follow-up of 19 months, all patients are alive. Conclusions: Neoadjuvant therapy with irinotecan combined with 5-FU/FA enabled a significant proportion of patients with initially unresectable liver metastases to undergo surgical resection. The effects of treatment on survival have yet to be determined.
Inglese
Pozzo, C., Basso, M., Cassano, A., Quirino, M., Schinzari, G., Trigila, N., Vellone, M., Giuliante, F., Nuzzo, G., Barone, C. A., Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients, <>, 2004; 15 (6): 933-939. [doi:10.1093/annonc/mdh217] [http://hdl.handle.net/10807/14758]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/14758
Citazioni
  • ???jsp.display-item.citation.pmc??? 49
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact